All In MedTech

Device Trial Radar · NCT07174622

Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation

Real-world Clinical Outcomes in Medicare Patients With Hypertension Treated With Symplicity Renal Denervation Plus Standard of Care Versus Standard of Care in Integrated EHR and Claims Data

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Jun 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Medtronic VascularPublic (MDT)
Sponsor type
Industry
First posted
Sep 16, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This observational study will assess the long-term effectiveness of the RDN procedure for lowering blood pressure in Medicare patients with uncontrolled hypertension. This research will be conducted using de-identified electronic health records (EHR) and administrative health insurance claims data. Patients are enrolled through the submission of claims or encounter data to CMS.

Conditions

  • Hypertension
  • Cardiovascular Diseases
  • Vascular Diseases

Interventions

  • Renal Denervation (Symplicity Spyral™)Device

    Symplicity Spyral™ multi-electrode renal denervation system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Office Systolic Blood Pressure (OSBP)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.